end of the downside- back in, page-63

Fair enough. I just thought the 2014 trial results would've have been the cause of the poor share price performance, because some scientific types (e.g. on alzforum.org's analysis of pbt2 results) seem to have differing opinions on whether the result meant the trial was a failure or not - hence rendering the trial inconclusive. Could be both management ineptitude and the trial result I guess. In any case, if future clinical trial data is conclusive and positive, I don't see a repeat of past poor performance. IMO.